EPRX Stock Forecast & Price Target

Eupraxia Pharmaceuticals is attractive fundamentally because EP-104GI has shown durable efficacy with 66% of Cohort 9 patients in SDI-defined clinical remission through Week 52 and 64% of evaluable Cohorts 5–9 patients remaining in remission at one year, supporting a differentiated once-yearly profile. The safety data are equally compelling, with no treatment-emergent or procedure-related serious adverse events, no oropharyngeal candidiasis, no adrenal insufficiency, and no glucose derangement, which strengthens the case for long-term use versus chronic swallowed steroids. Financially, the company had $133.7MM of cash, cash equivalents, and marketable securities as of 2Q26 and believes this supports operations into 2H28, while the combination of a large and growing EoE market, 2 programs, and a Phase 2b-ready knee OA asset adds multiple shots on goal.

Eupraxia Pharmaceuticals is a clinical-stage biotech with no approved commercial products, so its valuation depends heavily on EP-104GI succeeding in EoE and EP-104IAR advancing in knee osteoarthritis, both of which still carry meaningful clinical and regulatory risk. The bear case is strengthened by the possibility that EP-104GI underperforms against swallowed steroids or Eohilia on dysphagia and histologic benchmarks, while any new safety signal such as candidiasis above 5% could erase differentiation and force discontinuation. Financially, the company also faces dilution risk and ongoing royalty burdens to Auritec, including 4% of net sales and up to $100MM in additional monetization payments, limiting upside even if development progresses.